Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022GlobeNewsWire • 08/02/22
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022GlobeNewsWire • 07/25/22
Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpointMarket Watch • 06/22/22
Athira Pharma shares drop nearly 70% on release of clinical trial data for Alzheimer's diseaseGeekWire • 06/22/22
Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68%Market Watch • 06/22/22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 06/22/22
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology ResearchGlobeNewsWire • 06/07/22
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHABusiness Wire • 05/28/22
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 05/21/22
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual MeetingGlobeNewsWire • 05/19/22
Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy ContestGlobeNewsWire • 05/16/22
Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of DirectorsBusiness Wire • 05/16/22
Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira BoardBusiness Wire • 05/12/22
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual MeetingGlobeNewsWire • 05/11/22
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHABusiness Wire • 05/05/22
Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira's Highly Qualified Director NomineesGlobeNewsWire • 05/05/22
Leading Proxy Advisory Firm ISS Recommends Athira Shareholders “Withhold” Support From Incumbent Directors Joseph Edelman and John FlukeBusiness Wire • 05/05/22
Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy CardGlobeNewsWire • 05/04/22
Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is RequiredBusiness Wire • 04/27/22